FENC Q3 2024 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+7.0% YoY

Gross Profit

$6M80.5% margin

Operating Income

-$5M-74.6% margin

Net Income

-$6M-82.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$59M

Total Liabilities

$64M

Stockholders' Equity

-$5M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	+7.0%
Gross Profit	$6M	$6M	-9.2%
Operating Income	-$5M	-$1M	-411.5%
Net Income	-$6M	-$2M	-207.2%